The European Commission has drawn up plans to reduce the administrative burden on pharma firms and regulatory authorities caused by the growing number of applications for variations to marketing authorizations (MAs).
The proposals, which would streamline the current framework and speed up the handling of variation applications, have just been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?